Jefferies on Praxis Precision Medicines Inc. (PRAX): 'see 5%+ stock upside as FDA accepts the NDA for ulixacaltamide'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $525.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
